Meima-van Praag, E. M. http://orcid.org/0000-0002-0932-228X
Reijntjes, M. A. http://orcid.org/0000-0002-1047-8847
Hompes, R. http://orcid.org/0000-0001-6094-8950
Buskens, C. J. http://orcid.org/0000-0001-9425-8683
Duijvestein, M. http://orcid.org/0000-0003-4814-9376
Bemelman, W. A. http://orcid.org/0000-0002-1037-9945
Article History
Received: 22 April 2022
Accepted: 14 August 2022
First Online: 30 August 2022
Declarations
:
: None related to the current paper. EMP, MR, CB had none to declare. RH: Educational Grant: Stryker. Consulting fees: Applied Medical. Speaker fees: Applied Medical, Medtronic, Johnson & Johnson. Stock options: SurgEase. MD: Advisory fees: Echo Pharma, Alimentiv (formerly Robarts Clinical Trials). Unrestricted Grant: Pfizer. Speaker fees: Janssen, Merck & Co., Inc., Pfizer, Takeda, Tillotts Pharma, Galapagos, BMS. Nonfinancial support: Dr. Falk Pharma. WB: Speaker fees: Takeda, Johnson & Johnson, Medtronic, Braun. Grant: VIFOR, Braun.
: According to local law and the Medical Ethical Committee at the Amsterdam UMC, ethical approval was waived for this retrospective study.
: All eligible patients received an opt-out letter and could withdraw permission to collect data for this study.